Efficacy of M118, a Rationally-Engineered Low-Molecular-Weight Heparin, in a Canine Model of Arterial Thrombosis Ian D Fier1, Mark A Nedelman1, J Luis Guerrero2, Ganesh Venkataraman1, and Yi Wei Qi1 Momenta Pharmaceutica

First Page		Document Content
Date: 2012-06-27 15:00:31 Heparins Anatomy Low molecular weight heparin Factor X Coagulation UFH Antithrombin Partial thromboplastin time Anticoagulant Blood Coagulation system Hematology		Efficacy of M118, a Rationally-Engineered Low-Molecular-Weight Heparin, in a Canine Model of Arterial Thrombosis Ian D Fier1, Mark A Nedelman1, J Luis Guerrero2, Ganesh Venkataraman1, and Yi Wei Qi1 Momenta Pharmaceutica Add to Reading List Source URL: www.momentapharma.com Download Document from Source Website File Size: 314,43 KB Share Document on Facebook

	Biomolecular Interaction and The Interactome.doc DocID: 1pQMx - View Document
	Domestic Sales Outsourcing Agreement for Recombinant Human Antithrombin Preparation Signed Tokyo, Japan, July 30, The Japan Blood Products Organization (head office: Tokyo, Japan, President and representative di DocID: 1lLMs - View Document
	Paris, 19 MayPress releaseGTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent, and is also granted new patent on recombinant antithrombin pro DocID: 1aPBm - View Document
	Routine Coagulation Reagents Activated Partial Thromboplastin Time (aPTT) Antithrombin III (ATIII) Prothrombin Time (PT) Thrombin Time (TT) Fibrinogen DocID: 1aOgJ - View Document
	HAEMATOLOGIC TECHNOLOGIES INCResearch Reagents Catalog DocID: 1apfC - View Document